Johnson & Johnson (NYSE: JNJ), the biggest maker of consumer health products, said it will acquire Alios BioPharma Inc., a developer of viral disease therapies.

J&J will pay $1.75 billion in cash for closely held Alios. The San Francisco target develops treatments for influenza, rhinoviruses and respiratory syncytial virus, which causes infections in infants and has no approved preventative therapy.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.